Shattuck Labs Inc (STTK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.79-2.44%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · STTK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -31.5% |
| Our one-year growth estimate | diamond | -81.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 49.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
STTK — debt issuance
Dated 2026-06-11
Entry into a Material Definitive Agreement. Underwritten Public Offering On June 9, 2026, Shattuck Labs, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Leerink Partners LLC, J.P. Morgan Securities LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as the representatives of the underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,879,376 shares of the Company’s common stock, par value $0.0001 per shar…
Why it matters: If the healthcare sector's revenue growth speeds up, it could benefit Shattuck Labs.
Supportive ifHealthcare sector revenue growth exceeds 10% year over year.
Worry ifHealthcare sector revenue growth remains below 5% year over year.
Why it matters: Updates on cash will show if Shattuck can pay for operations through 2029. This affects financial health.
Watch forCash and cash equivalents are over $200 million. This means funding is secure through 2029.
Also watch forCash reserves fall below $200 million. This raises worries about funding.
Why it matters: Updates on cash flow after the stock offering will show how well Shattuck can fund its operations. This is key for long-term growth.
Watch forShattuck has cash flow to support operations until 2029 after the stock offering.
Also watch forCash flow updates show a shorter time frame than expected. This raises funding concerns.
Why it matters: Data from the Phase 1 trial will show safety and effectiveness. This will affect future trials.
Supportive ifThe Phase 1 trial data shows good safety and effectiveness results.
Worry ifThe data release is late. It shows big safety or effectiveness problems.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$306 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $670 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,051 loss on $10,000 · 50.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Details about the debt will show financial health and future funding plans.
Watch forDebt issuance closes well with good terms and strong investor interest.
Also watch forDebt issuance faces strong investor resistance or bad terms.
Why it matters: Maintaining cash flow is crucial for funding operations into 2029. Investors need to see how well this strategy works.
Supportive ifThey completed stock offerings that raised at least $20 million.
Worry ifStock offerings do not raise the expected funds or are delayed a lot.
Why it matters: Data from this study will inform the safety of SL-846, a key product candidate. Positive results could enhance the pipeline.
Supportive ifThe first safety data from the SL-846 study will be shown at UEG Week in October 2026.
Worry ifNo data is shown or results raise major safety worries.
Why it matters: Safety data for SL-846 will be crucial for its potential market entry and future trials.
Supportive ifThe SL-846 toxicology study shows good safety. It also shows a strong immune response.
Worry ifSafety data shows major concerns or delays in getting results.
Why it matters: Updates on cash flow will show if Shattuck can fund operations into 2029 as planned.
Supportive ifManagement says cash flow is steady. It can support operations until 2029.
Worry ifManagement reports cash flow problems or needs more money before 2029.
Why it matters: The start of this trial is key for testing SL-325 in Crohn's disease. Positive results could boost the drug's potential in the market.
Supportive ifThe Phase 2b clinical trial of SL-325 in Crohn's disease starts as planned in Q3 2026.
Worry ifThe trial initiation is delayed beyond Q3 2026.
Why it matters: Initial data for SL-846 will show its promise as a bispecific antibody. This could greatly expand Shattuck's product line.
Supportive ifInitial Phase 1 clinical data for SL-846 is released in 2027.
Worry ifPhase 1 data for SL-846 is delayed beyond 2027.